Menü Logo

Gestational trophoblastic disease in the western region of Saudi Arabia (single-institute experience).

Eur J Obstet Gynecol Reprod Biol. 2014 Sep;180:8-11. doi: 10.1016/j.ejogrb.2014.06.005. Epub 2014 Jun 17.

Anfinan N1, Sait K2, Sait H1.

Eur J Obstet Gynecol Reprod Biol
AbstractOBJECTIVE: To estimate the prevalence of gestational trophoblastic disease (GTD) in the western region of Saudi Arabia, and to evaluate the success of treatment and the effect of age and risk group on survival.METHODS: Between January 2001 and December 2010, all patients treated for GTD were identified from the King Abdulaziz University Hospital database. Patients with persistent disease were evaluated according to their clinical treatment outcomes.RESULTS: In total, 122 cases of GTD were identified in the database. Of these, 77 (63%) cases were diagnosed and received initial treatment at the study centre, resulting in an incidence of 1.26 cases per 1000 deliveries. The mean (±standard deviation) age of the study participants was 31.52±10.8 years, mean gestational age at diagnosis was 12.42±3.2 weeks, and mean follow-up for each patient was 24 months. There were 20 cases (26%) of persistent GTD after treatment. The majority of patients with low-risk disease were treated with single-agent methotrexate, with an overall success rate of 83%. The overall 5-year survival rate for all patients was 98%. Using the Wilcoxon (Gehan) test, risk group and age (cut-off 40 years) were not found to be significantly associated with survival (p=0.69).CONCLUSIONS: This single-institute study reports the first survival data for GTD for Saudi Arabia. However, the overall incidence of GTD in Saudi Arabia will be defined by establishment of a GTD registry.Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
Full Text Source: Elsevier Science
PMID:24972119 |

Um den vollständigen Inhalt zu sehen, müssen Sie sich einloggen oder sich auf registrieren.

Jetzt einloggen

Passwort vergessen

Jetzt kostenlos registrieren

Mit einer Anmeldung bei haben Sie Zugriff auf: DFP-Kurse, Arzneimittelinfos, Produktfortbildungen und mehr.

Loggen Sie sich ein oder registrieren Sie Ihren kostenlosen Account.